← 返回

可规模化用于临床应用的人外周血 NK 细胞分离与扩增方案

英文原题:Protocol for isolation and expansion of natural killer cells from human peripheral blood scalable for clinical applications.

查看英文原题

Protocol for isolation and expansion of natural killer cells from human peripheral blood scalable for clinical applications.

PubMed 2025/02/26(内容时间) Biol Methods Protoc Q3 · IF 2.4(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

自然杀伤(NK)细胞已成为针对多种恶性肿瘤的新型免疫治疗策略中颇具前景的候选者。其无需预先致敏即可识别并清除肿瘤细胞的独特能力,加之可分泌干扰素-γ和肿瘤坏死因子等促炎细胞因子,使其成为癌症治疗中极具潜力的效应细胞。过继性NK细胞输注在血液系统恶性肿瘤中已显示出特别的前景,NK细胞输注可使高比例的患者获得缓解。

此外,通过工程化改造使NK细胞表达嵌合抗原受体,可进一步增强其疗效,从而将其适用范围拓展至实体瘤。持续开展的研究对于优化NK细胞疗法、增强其疗效以扩大临床应用至关重要。

然而,此类研究有赖于稳健的NK细胞分离、扩增及基因工程改造方案与实验方法学。为尝试建立NK细胞分离与扩增的标准化方案,我们提出了一套经过充分测试与验证的方案,该方案可制备出高度纯净、具有活力且功能强大的NK细胞,可用于NK细胞疗法的研究与开发。该方案具有高度可重复性,严格遵循药品生产质量管理规范(Good Manufacturing Practice)法规要求,并已通过可扩展性测试,能够以临床相关剂量制备NK细胞,以支持即用型NK产品的开发。

展开英文摘要原文

Natural killer (NK) cells have emerged as promising candidates for novel immunotherapy strategies against various malignancies. Their unique ability to recognize and eliminate tumour cells without prior sensitization, coupled with the secretion of pro-inflammatory cytokines such as interferon-gamma and tumour necrosis factor, position them as promising agents in cancer therapy. Adoptive NK cell transfer has shown particular promise in haematological malignancies, where NK cell infusions could achieve remission in a high proportion of patients.

Moreover, the possibility to engineer NK cells to express chimeric antigen receptors can further enhance their efficacy, thereby broadening their applicability to include solid tumours. Ongoing research is crucial to optimize NK cell therapies and enhance their efficacy to expand their clinical applications.

However, this research hinges on robust protocols and experimental methodology for the isolation, expansion, and genetic engineering of NK cells. In an attempt to set up a standardized protocol for NK cell isolation and expansion, we present a thoroughly tested and validated protocol that can produce highly pure, viable, and potent NK cells that can be used for research and development of NK cell therapies.

The protocol is highly reproducible, closely aligned to comply with Good Manufacturing Practice regulations, and tested for scalability to produce NK cells at clinically relevant dosages to support the development of off-the-shelf NK products.

论文信息

作者
Kundu S、Durkan L、O'Dwyer M、Szegezdi E
单位
School of Biological and Chemical Sciences, University of Galway, Galway, H91 TK33, Ireland.Ireland
期刊
Biology methods & protocols2025
原文标识
PubMed 40060948 · DOI 10.1093/biomethods/bpaf015